Document is current
Any future updates will be listed below
-
Authors
Perschinka, Fabian https://orcid.org/0000-0003-0677-8756
Köglberger, Paul https://orcid.org/0000-0002-1772-5214
Köhler, Andrea
Lehner, Georg Franz
Peer, Andreas
Maier, Sarah https://orcid.org/0000-0002-7012-3669
Ulmer, Hanno https://orcid.org/0000-0001-5911-1002
Bellmann, Romuald https://orcid.org/0000-0003-2861-3258
Forni, Lui G. https://orcid.org/0000-0002-0617-5309
Joannidis, Michael https://orcid.org/0000-0002-6996-0881
-
Funding
Funding for this research was provided by:
Baxter Healthcare Corporation
University of Innsbruck and Medical University of Innsbruck
- License Information
-
More Information
Article History
Received: 13 July 2025
Accepted: 16 October 2025
First Online: 17 November 2025
Declarations
:
: FP, PK, GL, AK, AP, SM, and HU declare that they have no competing interests. LGF has received research support from NIHR and Baxter/Vantive, consulting fees from AstraZeneca and SpingoTec, and lecture fees from Vantive. LGF has stocks or stock options for Liom and SciLogica. LGF is a member of the ISCCN. RB has received research support from Pfizer and Austrian Research Fund (FWF), research support from Rokitan, consulting fees from Mundipharma as well as lecture fees from Gilead and Pfizer. RB is a head of the clinical section of the Austrian society of Clinical Pharmacology, Head of the Section Antimycotic Therapy of the Paul-Ehrlich-Society and a member of the hospital drug committee in Innsbruck. MJ has received grants from Baxter/Vantive and Fresenius, consulting fees from Baxter/Vantive, AmPharma, Biomerieux, SphingoTec, and Novartis as well as lecture fees from Baxter, Biomerieux, and AOP, and is a member of ISCCN.
: The study was approved by the ethics committee of the Medical University of Innsbruck (1221/2019) on 19st September 2019. The study was performed in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines.
: Not applicable.
